Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

被引：208
作者：
Haslam, Alyson [1 ,2 ]
Gill, Jennifer [1 ]
Prasad, Vinay [1 ,3 ,4 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Oncol, Portland, OR 97201 USA
[2] Oklahoma State Univ, Ctr Hlth Sci, 700 N Greenwood Ave,Main Hall,Ste 1400, Tulsa, OK 74106 USA
[3] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Dept Med, Div Gen Med, Portland, OR 97201 USA
来源：
JAMA NETWORK OPEN | 2020年 / 3卷 / 03期
关键词：
D O I：
10.1001/jamanetworkopen.2020.0423
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 5 条
[1]  
American Cancer Society, 2018, IMM CHECKP INH TREAT
[2]   A reality check of the accelerated approval of immune-checkpoint inhibitors [J].
Gill, Jennifer ;
Prasad, Vinay .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (11) :656-658
[3]   Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs [J].
Haslam, Alyson ;
Prasad, Vinay .
JAMA NETWORK OPEN, 2019, 2 (05)
[4]  
U.S. Food and Drug Administration, 2018, FDA LIM US TEC KEYTR
[5]  
University of Geneva, 2019, PUBL DOM ANT FOUND H
1